A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
150actual
Sites
52
Countries
Czechia, Japan, Poland +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-30 | actual | When the study began enrolling |
| Primary completion | 2026-02-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-09 | actual | The whole study's end, after follow-up |
| First posted | 2025-01-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dermatitis Atopic
Interventions
- Drug: Lunsekimig — also filed as SAR443765
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent change in Eczema Area and Severity Index (EASI) score from baseline to Week 24
measured From Baseline throughout the study, up to Week 24
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed